Table 3.
Patient-reported outcomes at baseline and week 12 (for n = 13 study completers).
| Outcome | Timepoint | Mean | SD | N | p value | 95% CI | |
|---|---|---|---|---|---|---|---|
| BLCS | Baseline | 9.40 | 5.27 | 5 | 0.38 | -5.02 | 10.62 |
| Week 12 | 6.60 | 3.05 | 5 | ||||
| ABSST-9 | Baseline | 17.5 | 5.66 | 8 | 0.37 | −4.13 | 10.13 |
| Week 12 | 14.5 | 4.04 | 4 | ||||
| MSWS-12 | Baseline | 34.38 | 11.06 | 8 | 0.94 | −7.46 | 7.96 |
| Week 12 | 34.13 | 13.89 | 8 | ||||
| STEPS | Baseline | 5778 | 3231 | 19 | 0.44 | 4490 | 8030 |
| Week 12 | 6263 | 3943 | 19 | ||||
| CES-D | Baseline | 39.13 | 6.31 | 8 | 0.07 | −0.87 | 15.12 |
| Week 12 | 32.00 | 12.44 | 8 | ||||
BLCS: Bladder Control Scale; ABSST-9: Actionable Bladder Symptoms Screening Tool; MSWS12: Multiple Sclerosis Walking Scale; STEPS: average daily step count; CES-D: Center for Epidemiological Studies Depression.